GLP-1 & Obesity Drugs: A Mega-Trend Becomes a One-Winner Market

Is the GLP-1 trend over?

The market is still growing — but the trend stopped lifting all boats. This is the most instructive maturation story on our list: two companies rode the same wave for three years, and in 2026 one is compounding while the other is shrinking.

Eli Lilly raised its 2026 revenue guidance to $85–87 billion (recent quarters growing ~48% year over year) and holds roughly 61% of the US obesity/diabetes market. Novo Nordisk guided to a 5–13% decline in sales and profit for 2026, suffered a failed late-stage cardiovascular trial that erased $30 billion of market value in a day, and saw its new obesity pill miss sales estimates.

How did the trend rise and split?

• 2021–2022 — the discovery phase. Clinical results show GLP-1 drugs producing weight loss once thought impossible without surgery. Both Novo (Ozempic/Wegovy) and Lilly (Mounjaro) stocks begin historic runs.
• 2023–2024 — the mania phase. Supply can't meet demand; both companies race capacity expansion; the market prices a duopoly splitting a $100B+ future market. Novo briefly becomes Europe's most valuable company. Everything obesity-adjacent re-rates (and everything obesity-threatened — snacks, dialysis, devices — de-rates).
• 2025 — the divergence. Lilly's Zepbound/Mounjaro franchise out-grows Novo's; combined Lilly obesity/diabetes sales (~$36B) overtake Novo's. Novo stock has a brutal year while Lilly consolidates.
• 2026 — the resolution. Lilly guides to $85–87B (raised); Novo guides to declining sales and profit, fails a major cardiovascular trial ($30B single-day wipeout), and fumbles its oral launch despite being first to market with a pill. The duopoly thesis is dead: it is Lilly's market.

Three years from "both stocks can't lose" to "only one stock can win" — that is how fast mega-trend economics consolidate.

The scoreboard

Metric (as of Aug 8, 2026)	Eli Lilly	Novo Nordisk
2026 guidance	$85–87B revenue, raised	Sales/profit declining 5–13%
US obesity/diabetes share	~61%	~39%
Stock YTD	+4%	~-10% (after a brutal 2025)
Oral pill	Orforglipron launching into franchise momentum	First to market, but missed sales estimates

Why is Lilly only up 4% if it's winning?

Size and expectations. At a trillion-dollar-plus scale with pharma multiples, even 25%+ growth is "expected." The explosive-return phase of this trend (2021–2024) is over; what remains is a quality compounder (Lilly) and a cautionary tale (Novo). That is what mature trends look like.

The metrics that matter

• US prescription share trend — the 61/39 split has widened every quarter; stabilization would be Novo's first green shoot, further widening confirms the one-winner thesis.
• Oral GLP-1 uptake — the pill era (orforglipron's launch) expands the market beyond injectables; its trajectory decides the next $20B+ of TAM.
• Pricing per patient — competition and political pressure push US prices down; volume growth must outrun price decline for revenue to keep compounding.
• Pipeline readouts beyond weight loss — cardiovascular, sleep apnea, kidney, and addiction indications each expand insurable demand; Novo's ziltivekimab failure shows the downside of a readout.
• Supply/capacity announcements — the constraint that defined 2023–24 has eased; watch for capacity outrunning demand as the cycle's eventual risk.
• Patent cliffs and compounding competition — Novo's semaglutide loses exclusivity in key international markets; generics and next-gen competitors define the late-decade landscape.

Second-order plays

Expression	Names	Angle
The challenger pipeline	Viking Therapeutics (VKTX), smaller biotechs	High-risk bets on next-generation candidates; acquisition targets
Manufacturing picks-and-shovels	Catalent-style CDMOs, injector/device makers	Capacity buildout beneficiaries regardless of which drug wins
The "loser" basket — reversed	Snacks, dialysis, bariatric devices	Names crushed by GLP-1 fear in 2023–24; some have already mean-reverted as fears overshot
Distribution disruption	Telehealth prescribers, pharmacy benefit managers	The channel fight over who dispenses the era's biggest drug class

The bear case on the whole theme, steelmanned

Even Lilly is not riskless. First, pricing is a political target: obesity drugs at scale strain every insurance system; US price-control action against the category is a persistent tail risk that would compress the market's value even as volumes grow. Second, the market may be smaller than modeled: real-world discontinuation rates are high (cost, side effects), and lifetime-therapy revenue models assume persistence that hasn't been demonstrated at population scale. Third, competitive entropy: with a market this large, every major pharma is developing candidates; the 61% share that justifies Lilly's premium is a moving target once oral competition matures. Fourth, Novo as a warning, not a bargain: cheap-looking laggards in one-winner markets historically keep losing — "it's half its old price" was true of Novo all the way down.

The bull rebuttal: obesity is the largest under-treated condition in the developed world, penetration is still single-digit, and Lilly's execution lead is compounding, not shrinking. Mature does not mean over.

The statin-era analogy

The closest pharma precedent is the statin era (1990s–2000s): a drug class that redefined preventive medicine, minted one dominant winner (Lipitor made Pfizer the sector's giant) among several competitors, sustained blockbuster economics for over a decade — and eventually succumbed to patent cliffs and generics. The mapping: GLP-1s are tracking the same arc at larger scale. The lesson for stock pickers: the dominant statin franchise rewarded holders for years after the "trend" felt old — category kingship compounds quietly. The caveat: the also-ran statin makers underperformed the whole time. Own the king or skip the category.